This is a 112-week (approximately two-year) open-label extension study of Beremagene Geperpavec (B-VEC), for participants aged 2 months and older, who have been diagnosed with Dystrophic Epidermolysis Bullosa (DEB). Participants will be dosed weekly with the topical B-VEC therapy. The primary endpoint will be to assess long term safety and tolerability of the topical gene therapy. The study is for those who participated in Phase 3 study, as well as, new participants who were unable to participate in the Phase 3 study, who meet all enrollment criteria.

Inclusion Criteria:

• Willing and able to give consent/assent
• Clinical diagnosis of epidermolysis bullosa
• Confirmation of diagnosis (either DDEB or RDEB) by genetic testing including COL7A1.
• Age: 2 months of age and older at the time of informed consent/assent
• Women of childbearing age must be willing to use reliable birth control method throughout the treatment duration and for 3 months following the last treatment application

Exclusion Criteria:

• Diseases or conditions that could interfere with the assessment of safety of the study treatment and compliance of the participant with study visits/procedures, as determined by the Investigator
• Pregnant or nursing women
• Active infection in the area that will undergo administration, that the Investigator believes will negatively impact the IP application
• Known allergy to any of the constituents of the product
• Concurrent skin transplant or mesh skin grafting; if the participant is currently having transplantation or grafting surgeries they must wait until the transplant has begun to heal and the graft has absorbed prior to initiating B-VEC therapy
• Participation in an interventional gene therapy clinical trial within the past three (3) months (not including B-VEC administration)